Calculation of Filing Fee Tables
Form S-8
(Form Type)
Cidara Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| Table 1 – Newly Registered Securities |
| Security Type | Security Class Title | Fee Calculation Rule | Amount Registered(1) | Proposed Maximum Offering Price Per Unit | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee |
| Fees to be Paid | Equity | Cidara Therapeutics, Inc. 2015 Employee Stock Purchase Plan Common Stock, $0.0001 par value per share | Other(3) | 24,516(2) | $19.530(3) | $478,798 | 0.0001531 | $74 |
| Fees to be Paid | Equity | Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, as amended Common Stock, $0.0001 par value per share | Other(5) | 350,000(4) | $22.977(5) | $8,041,950 | 0.0001531 | $1,232 |
| Total Offering Amounts | | $8,520,748 | | $1,306 |
| Total Fee Offsets | | | | – |
| Net Fee Due | | | | $1,306 |
(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of common stock, par value $0.0001 per share (“Common Stock”), of Cidara Therapeutics, Inc. (the “Registrant”) that become issuable under the Cidara Therapeutics, Inc. 2015 Employee Stock Purchase Plan (the “ESPP”) and the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, as amended (the “Inducement Plan”) by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without receipt of consideration which results in an increase in the number of outstanding shares of Common Stock.
(2) Represents shares of Common Stock that were automatically added to the shares authorized for issuance under the ESPP on January 1, 2025 pursuant to an “evergreen” provision contained in the ESPP. Pursuant to such provision, on January 1 of each calendar year through 2025, the number of shares authorized for issuance under the ESPP is automatically increased by a number equal to the lesser of: (a) 1% of the total number of shares of capital stock outstanding on December 31 of the preceding calendar year; (b) 24,516 shares; or (c) a lesser number of shares of Common Stock as is determined by the Registrant’s board of directors (the “Board”) that is less than (a) and (b).
(3) This estimate is made pursuant to Rule 457(h)(1) and Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee. The price per share and aggregate offering price are based upon the average of the high and low prices of the Common Stock on February 27, 2025, as reported on the Nasdaq Capital Market, multiplied by 85%, which is the percentage of the price per share applicable to purchases under the ESPP.
(4) Represents an increase in the number of shares of Common Stock reserved for issuance under the Inducement Plan pursuant to an amendment to the Inducement Plan approved by the Compensation and Human Capital Committee of the Board on February 12, 2025.
(5) This estimate is made pursuant to Rule 457(h)(1) and Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee. The price per share and aggregate offering price are based upon the average of the high and low prices of the Common Stock on February 27, 2025, as reported on the Nasdaq Capital Market.
